The effect of CELLFOOD
CELLFOODTM
HIF1α
combined treatment strategies
mesothelioma
radiosensitivity
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
02
2019
accepted:
04
09
2019
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
31
10
2019
Statut:
epublish
Résumé
Based on previous observations that the nutraceutical CELLFOOD™ (CF), the 'physiological modulator' that aimed to make oxygen available 'on demand', inhibits the growth of cancer cells, this study was designed to investigate the role of CF in the regulation of hypoxia-inducible factor 1 alpha (HIF1α) and its correlated proteins, phosphoglycerate kinase 1 and vascular endothelial growth factor. Our idea was that CF, acting on HIF1α, in combination with current anticancer therapies could improve their effectiveness. To evaluate the effect of CF in association with radiotherapy and chemotherapy, different human cancer cell lines and mice with mesothelioma were analysed by tumour growth, clonogenic assay, western blot and immunohistochemical analysis. CF in combination with radiation with or without cisplatin increases the death rate of cancer cells. Collectively, results from preclinical trials suggest that CF could be a useful intervention to improve the efficacy of radiotherapy or combined treatment strategies and could be a promising treatment modality to counteract cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Based on previous observations that the nutraceutical CELLFOOD™ (CF), the 'physiological modulator' that aimed to make oxygen available 'on demand', inhibits the growth of cancer cells, this study was designed to investigate the role of CF in the regulation of hypoxia-inducible factor 1 alpha (HIF1α) and its correlated proteins, phosphoglycerate kinase 1 and vascular endothelial growth factor. Our idea was that CF, acting on HIF1α, in combination with current anticancer therapies could improve their effectiveness.
METHODS
METHODS
To evaluate the effect of CF in association with radiotherapy and chemotherapy, different human cancer cell lines and mice with mesothelioma were analysed by tumour growth, clonogenic assay, western blot and immunohistochemical analysis.
RESULTS
RESULTS
CF in combination with radiation with or without cisplatin increases the death rate of cancer cells.
CONCLUSIONS
CONCLUSIONS
Collectively, results from preclinical trials suggest that CF could be a useful intervention to improve the efficacy of radiotherapy or combined treatment strategies and could be a promising treatment modality to counteract cancer.
Identifiants
pubmed: 31662796
doi: 10.1177/1758835919878347
pii: 10.1177_1758835919878347
pmc: PMC6792276
doi:
Types de publication
Journal Article
Retracted Publication
Langues
eng
Pagination
1758835919878347Commentaires et corrections
Type : RetractionIn
Informations de copyright
© The Author(s), 2019.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
Int J Mol Sci. 2018 Oct 06;19(10):null
pubmed: 30301213
Int J Mol Med. 2011 Sep;28(3):449-54
pubmed: 21667015
Oncotarget. 2015 Jul 10;6(19):16848-65
pubmed: 26078352
JAMA Oncol. 2017 Aug 1;3(8):1120-1129
pubmed: 27978552
Clin Cancer Res. 2007 Oct 1;13(19):5670-4
pubmed: 17908955
Oral Oncol. 2017 Oct;73:105-110
pubmed: 28939061
Biochim Biophys Acta. 2004 Apr 1;1691(1):17-22
pubmed: 15053920
Proteomics. 2006 Apr;6(7):2259-72
pubmed: 16493704
Phys Med Biol. 2018 Mar 16;63(6):065012
pubmed: 28862152
Anticancer Res. 2011 Oct;31(10):3369-75
pubmed: 21965748
Int J Radiat Biol. 2015 Mar;91(3):294
pubmed: 25650895
Oncotarget. 2017 Jul 5;8(33):55073-55083
pubmed: 28903403
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
Acta Physiol Scand. 2003 Nov;179(3):233-41
pubmed: 14616239
Explore (NY). 2013 Jul-Aug;9(4):244-8
pubmed: 23906103
Cancer Lett. 2011 Sep 28;308(2):134-43
pubmed: 21669489
Curr Pharm Des. 2006;12(21):2673-88
pubmed: 16842166
Int J Cancer. 2010 Mar 15;126(6):1513-20
pubmed: 19688824
J Exp Clin Cancer Res. 2014 Mar 05;33:24
pubmed: 24598211
Cancer Res. 2010 Feb 1;70(3):925-35
pubmed: 20103649
Curr Med Chem. 2014;21(26):3021-8
pubmed: 24735366
J Thorac Dis. 2014 May;6 Suppl 2:S238-52
pubmed: 24868442
Nat Rev Cancer. 2002 Jan;2(1):38-47
pubmed: 11902584
Int J Oncol. 2013 Aug;43(2):586-90
pubmed: 23727790
Cancer Res. 2010 Mar 1;70(5):2010-9
pubmed: 20179204
Cell Mol Life Sci. 2019 Feb;76(3):453-471
pubmed: 30317527
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
J Physiol Pharmacol. 2011 Jun;62(3):287-93
pubmed: 21893688
BMC Cancer. 2015 Jul 25;15:547
pubmed: 26205780
ISRN Surg. 2014 Feb 03;2014:817203
pubmed: 24624305
Neoplasia. 2009 Oct;11(10):976-86
pubmed: 19794957
Curr Pharm Des. 2014;20(17):2834-42
pubmed: 23944367
FASEB J. 2004 Dec;18(15):1906-8
pubmed: 15456741
Cancer Sci. 2012 Feb;103(2):203-9
pubmed: 22017350
Oncotarget. 2016 Jul 26;7(30):47116-47126
pubmed: 27323398
Genes Cancer. 2016 Nov;7(11-12):340-354
pubmed: 28191281
Med Phys. 2012 Jul;39(7):4502-14
pubmed: 22830782
Radiother Oncol. 2010 Jan;94(1):102-9
pubmed: 20036432
Nat Rev Cancer. 2008 Jul;8(7):545-54
pubmed: 18511937
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
Free Radic Biol Med. 2018 Feb 1;115:266-277
pubmed: 29229551
Anticancer Res. 2002 Jul-Aug;22(4):1933-41
pubmed: 12174867
Front Pharmacol. 2018 Jan 11;8:970
pubmed: 29375377
Ochsner J. 2012 Spring;12(1):70-9
pubmed: 22438785
J Exp Clin Cancer Res. 2018 Apr 23;37(1):87
pubmed: 29688867
Biomed Res Int. 2013;2013:685308
pubmed: 23509762
Trends Mol Med. 2001 Aug;7(8):345-50
pubmed: 11516994
Cancer Med. 2015 Sep;4(9):1394-403
pubmed: 26177855
PLoS One. 2010 May 07;5(5):e10522
pubmed: 20479887
Mol Cancer. 2008 Mar 26;7:27
pubmed: 18366759
J Cell Biochem. 2015 May;116(5):696-703
pubmed: 25546605
Mol Cancer Ther. 2009 Apr;8(4):947-58
pubmed: 19372568
J Biol Chem. 1994 Sep 23;269(38):23757-63
pubmed: 8089148
Molecules. 2015 Nov 19;20(11):20551-68
pubmed: 26610437
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104-9
pubmed: 9223322
J Exp Clin Cancer Res. 2013 Sep 09;32:63
pubmed: 24016597
Mol Cell Biol. 2008 Aug;28(16):5106-19
pubmed: 18559422
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Clin Breast Cancer. 2015 Apr;15(2):135-42
pubmed: 25454741
J Exp Clin Cancer Res. 2008 Sep 24;27:44
pubmed: 18811981
Mol Pharmacol. 2006 Nov;70(5):1469-80
pubmed: 16887934